Explore
Validate
Learn
Western blot
ELISAAntibody data
- Antibody Data
- Antigen structure
- References [7]
- Comments [0]
- Validations
- Western blot [1]
- Immunohistochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 11655-2-AP - Provider product page
- Provider
- Proteintech Group
- Proper citation
- Proteintech Cat#11655-2-AP, RRID:AB_2195738
- Product name
- SSR4 antibody
- Antibody type
- Polyclonal
- Description
- SSR4 antibody (Cat. #11655-2-AP) is a rabbit polyclonal antibody that shows reactivity with human, mouse, rat and has been validated for the following applications: IF, IHC, IP, WB, ELISA.
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references Unveiling SSR4: a promising biomarker in esophageal squamous cell carcinoma.
Single-cell RNA-seq combined with bulk RNA-seq analysis identifies necroptosis-related genes as therapeutic targets for periodontitis.
Eeyarestatin I (ESI)-induced ERAD inhibition exhibits anti-cancer activity through multiple mechanisms in human colorectal cancer cells.
Predicting Outcomes in Esophageal Squamous Cell Carcinoma Using scRNA-Seq and Bulk RNA-Seq: A Model Development and Validation Study.
Identification of Translocon-associated Protein Delta as An Oncogene in Human Colorectal Cancer Cells.
SSR4 as a prognostic biomarker and related with immune infiltration cells in colon adenocarcinoma.
The translocon-associated protein (TRAP) complex regulates quality control of N-linked glycosylation during ER stress.
Zhang J, Jia F, Li C, Song S, Gong A
Frontiers in immunology 2025;16:1544154
Frontiers in immunology 2025;16:1544154
Single-cell RNA-seq combined with bulk RNA-seq analysis identifies necroptosis-related genes as therapeutic targets for periodontitis.
Zhu F, Xu M, Xiao Y, Yao H, Liu F, Shi S, Huang R, Wu Q, Deng X
BMC medical genomics 2025 Oct 14;18(1):159
BMC medical genomics 2025 Oct 14;18(1):159
Eeyarestatin I (ESI)-induced ERAD inhibition exhibits anti-cancer activity through multiple mechanisms in human colorectal cancer cells.
Peng J, Wei CI, Lee SH
European journal of pharmacology 2025 Jun 15;997:177623
European journal of pharmacology 2025 Jun 15;997:177623
Predicting Outcomes in Esophageal Squamous Cell Carcinoma Using scRNA-Seq and Bulk RNA-Seq: A Model Development and Validation Study.
Zhang J, Song S, Li Y, Gong A
Cancer medicine 2025 Jan;14(2):e70617
Cancer medicine 2025 Jan;14(2):e70617
Identification of Translocon-associated Protein Delta as An Oncogene in Human Colorectal Cancer Cells.
Amarakoon D, Lee WJ, Peng J, Lee SH
Journal of cancer prevention 2024 Dec 30;29(4):175-184
Journal of cancer prevention 2024 Dec 30;29(4):175-184
SSR4 as a prognostic biomarker and related with immune infiltration cells in colon adenocarcinoma.
He W, Wang B, He J, Zhao Y, Zhao W
Expert review of molecular diagnostics 2022 Feb;22(2):223-231
Expert review of molecular diagnostics 2022 Feb;22(2):223-231
The translocon-associated protein (TRAP) complex regulates quality control of N-linked glycosylation during ER stress.
Phoomak C, Cui W, Hayman TJ, Yu SH, Zhao P, Wells L, Steet R, Contessa JN
Science advances 2021 Jan;7(3)
Science advances 2021 Jan;7(3)
No comments: Submit comment
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- HeLa cells were subjected to SDS PAGE followed by western blot with 11655-2-AP(SSR4 antibody) at dilution of 1:500
- Sample type
- cell line
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- The SSR4 antibody from Proteintech is a rabbit polyclonal antibody to a recombinant protein of human SSR4. This antibody recognizes human,mouse,rat antigen. The SSR4 antibody has been validated for the following applications: ELISA, IHC, WB analysis.
